Search research articles
Contact Us
Filters
Showing results (51-60 of 92) with videos related to
Page
of 10
Sort By:
Oncotarget
|
March 17, 2016
Ruxolitinib synergizes with DMF to kill via BIM+BAD-induced mitochondrial dysfunction and via reduced SOD2/TRX expression and ROS
Mehrad Tavallai, Laurence Booth, Jane L Roberts, et al.
Aging
|
July 12, 2021
Inhibition of heat shock proteins increases autophagosome formation, and reduces the expression of APP, Tau, SOD1 G93A and TDP-43
Paul Dent, Laurence Booth, Jane L Roberts, et al.
Journal of Cellular Physiology
|
January 9, 2020
Neratinib degrades MST4 via autophagy that reduces membrane stiffness and is essential for the inactivation of PI3K, ERK1/2, and YAP/TAZ signaling
Paul Dent, Laurence Booth, Andrew Poklepovic, et al.
The Journal of Dermatological Treatment
|
May 5, 2020
A novel plant-derived compound is synergistic with 5-fluorouracil and has increased apoptotic activity through autophagy in the treatment of actinic keratoses
Cameron E West, Shawn G Kwatra, Justin Choi, et al.
Cancer Biology & Therapy
|
December 9, 2014
Regulation of dimethyl-fumarate toxicity by proteasome inhibitors
Laurence Booth, Nichola Cruickshanks, Seyedmehrad Tavallai, et al.
Aging
|
October 13, 2022
AR12 increases BAG3 expression which is essential for Tau and APP degradation via LC3-associated phagocytosis and macroautophagy
Paul Dent, Laurence Booth, Jane L Roberts, et al.
Oncotarget
|
February 2, 2017
The HDAC inhibitor AR42 interacts with pazopanib to kill trametinib/dabrafenib-resistant melanoma cells in vitro and in vivo
Laurence Booth, Jane L Roberts, Cindy Sander, et al.
Biochemical Pharmacology
|
June 2, 2021
Osimertinib-resistant NSCLC cells activate ERBB2 and YAP/TAZ and are killed by neratinib
Paul Dent, Laurence Booth, Andrew Poklepovic, et al.
Cancer Biology & Therapy
|
September 30, 2015
Celecoxib enhances [sorafenib + sildenafil] lethality in cancer cells and reverts platinum chemotherapy resistance
Timothy Webb, Jori Carter, Jane L Roberts, et al.
Oncotarget
|
June 4, 2016
Multi-kinase inhibitors interact with sildenafil and ERBB1/2/4 inhibitors to kill tumor cells in vitro and in vivo
Laurence Booth, Thomas Albers, Jane L Roberts, et al.
Page
of 10
Search research articles
Search
Showing results (51-60 of 92) with videos related to
Sort By:
Page
of 10
Oncotarget
|
March 17, 2016
Ruxolitinib synergizes with DMF to kill via BIM+BAD-induced mitochondrial dysfunction and via reduced SOD2/TRX expression and ROS
Mehrad Tavallai, Laurence Booth, Jane L Roberts, et al.
Aging
|
July 12, 2021
Inhibition of heat shock proteins increases autophagosome formation, and reduces the expression of APP, Tau, SOD1 G93A and TDP-43
Paul Dent, Laurence Booth, Jane L Roberts, et al.
Journal of Cellular Physiology
|
January 9, 2020
Neratinib degrades MST4 via autophagy that reduces membrane stiffness and is essential for the inactivation of PI3K, ERK1/2, and YAP/TAZ signaling
Paul Dent, Laurence Booth, Andrew Poklepovic, et al.
The Journal of Dermatological Treatment
|
May 5, 2020
A novel plant-derived compound is synergistic with 5-fluorouracil and has increased apoptotic activity through autophagy in the treatment of actinic keratoses
Cameron E West, Shawn G Kwatra, Justin Choi, et al.
Cancer Biology & Therapy
|
December 9, 2014
Regulation of dimethyl-fumarate toxicity by proteasome inhibitors
Laurence Booth, Nichola Cruickshanks, Seyedmehrad Tavallai, et al.
Aging
|
October 13, 2022
AR12 increases BAG3 expression which is essential for Tau and APP degradation via LC3-associated phagocytosis and macroautophagy
Paul Dent, Laurence Booth, Jane L Roberts, et al.
Oncotarget
|
February 2, 2017
The HDAC inhibitor AR42 interacts with pazopanib to kill trametinib/dabrafenib-resistant melanoma cells in vitro and in vivo
Laurence Booth, Jane L Roberts, Cindy Sander, et al.
Biochemical Pharmacology
|
June 2, 2021
Osimertinib-resistant NSCLC cells activate ERBB2 and YAP/TAZ and are killed by neratinib
Paul Dent, Laurence Booth, Andrew Poklepovic, et al.
Cancer Biology & Therapy
|
September 30, 2015
Celecoxib enhances [sorafenib + sildenafil] lethality in cancer cells and reverts platinum chemotherapy resistance
Timothy Webb, Jori Carter, Jane L Roberts, et al.
Oncotarget
|
June 4, 2016
Multi-kinase inhibitors interact with sildenafil and ERBB1/2/4 inhibitors to kill tumor cells in vitro and in vivo
Laurence Booth, Thomas Albers, Jane L Roberts, et al.
Page
of 10